Bioavailability and Effectiveness of Transdermally Administered Morphine - Full Text View

Sponsors and Collaborators:	Alberta Cancer Board ACB Palliative Care Research Initiative
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00125684

Purpose

Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously.

Condition	Intervention	Phase
Cancer Pain	Drug: morphine	Phase I

MedlinePlus related topics: Cancer

Drug Information available for: BaseLine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Bio-availability Study
Official Title:	Bioavailability and Effectiveness of Transdermally Administered Morphine

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:

detectable morphine levels in serum

Estimated Enrollment:	6
Study Start Date:	July 2003
Study Completion Date:	July 2008
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Detailed Description:

Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously. Blood draws will be done after both dosing methods in order to compare blood levels of morphine by the different routes.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic cancer pain
Minimum baseline pain of 3/10
No change in medications over 3 days prior to study period
Ability to give informed consent
Willingness to undergo repeated blood sampling

Exclusion Criteria:

Use of morphine or codeine in 3 days prior to study
Known sensitivity to morphine
Prior anaphylactic reaction to any opioid
Clinically significant anemia

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00125684

Locations

Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2

Sponsors and Collaborators

Alberta Cancer Board

ACB Palliative Care Research Initiative

Investigators

Principal Investigator:

Neil Hagen

Alberta Cancerboard

More Information

Study ID Numbers:	10181
Study First Received:	July 29, 2005
Last Updated:	August 13, 2008
ClinicalTrials.gov Identifier:	NCT00125684
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

transdermal morphine
cancer
pain
bioavailability

pharmacokinetics
cancer related pain
stable baseline pain
currently taking opioids

Study placed in the following topic categories:

Morphine
Pain

Additional relevant MeSH terms:

Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics

Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 16, 2009